For more than 20 years, Interleukin-2 (IL2) was the preferred treatment for medically fit metastatic melanoma patients, but recently two new agents were approved for stage IV disease.
Click here to read the journal article.
Search Suggestions
For more than 20 years, Interleukin-2 (IL2) was the preferred treatment for medically fit metastatic melanoma patients, but recently two new agents were approved for stage IV disease.
Click here to read the journal article.
